News

Scientists discover that patients responded differently to the targeted therapy Sunitinib depending on the type of genetic abnormality in their cancer.

Markers discovered that may aid in the prediction of recurrence of prostate cancer.

This trial is important because it is one of the first to examine a methodology for personalizing cancer treatment.

Biovest is now eligible to submit a biologics license application (BLA) on a rolling basis.

European Consortium led By Xenomics' collaborative venture with leading European research center prepares for euro 2 million funding of tuberculosis clinical program.

Biomarker will use the RCP marker only for the diagnosis of breast cancer.

Newly appointed vice president of WellPoint brings important payer constituency into coalition.

XB-BIS integration with the MetaCore™ permits the user to integrate back and forth between expanding knowledge and enhanced application.

The method is expected to be synergistic with existing pharmacogenomic approaches.

Building on its 17 year history in oligonucleotide manufacture and analysis, Dalton can now use its expertise in synthesis and manufacturing of antisense oligonucleotides.